Differentiation of human acute myelogenous leukemia cells: therapeutic possibilities.
Human myeloid leukemia cells have a growth advantage over normal cells because they do not differentiate into functional end-cells but remain in the proliferative pool. Several agents have been identified as inducers of differentiation of leukemia cells; among them are the retinoids, 1 alpha,25-dihydroxyvitamin D3 and human tumor necrosis factor alpha, which will be discussed in the following chapter.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D002117:Calcitriol / Q000494:pharmacology / Q000627:therapeutic use; D002454:Cell Differentiation / Q000187:drug effects; D002986:Clinical Trials as Topic; D006801:Humans; D007942:Leukemia, Experimental / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000473:pathology*; D051379:Mice; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D012176:Retinoids / Q000494:pharmacology / Q000627:therapeutic use*; D014212:Tretinoin / Q000627:therapeutic use; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology / Q000627:therapeutic use
D011994:Recombinant Proteins; D012176:Retinoids; D014409:Tumor Necrosis Factor-alpha; D014212:Tretinoin; D002117:Calcitriol